Company profile: Futura Medical
1.1 - Company Overview
Company description
- Provider of proprietary transdermal solutions. Products include Eroxon, a topical gel for erectile dysfunction that helps men achieve an erection within 10 minutes without a prescription, and DermaSys, a patented platform for delivering treatments via the skin tailored to specific therapeutic indications and desired speed of onset and duration.
Products and services
- DermaSys®: Patented technology platform delivers medical treatments via the skin, tailored for specific therapeutic indications with desired speed of onset and duration of action
- Eroxon®: Non-prescription topical gel for erectile dysfunction engineered to help men achieve an erection within 10 minutes without the need for a prescription
- Advanced Proprietary Transdermal Technology: Proprietary development approach applies advanced science to develop products with compelling commercial potential using advanced proprietary transdermal technology
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Futura Medical
Roquefort Therapeutics
HQ: United Kingdom
Website
- Description: Provider of pre-clinical anti-cancer therapeutics, including Midkine-targeting antibodies; antisense oligonucleotides to reduce Midkine in cancer cells; gene-editing RNA and mRNA therapies for solid tumors; STAT-6 siRNA therapeutics; and MK cell therapy with direct and NK cell-mediated action, advancing candidates toward clinical trials.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Roquefort Therapeutics company profile →
Cyclo Therapeutics
HQ: United States
Website
- Description: Provider of cyclodextrin-based therapeutics, including Trappsol® Cyclo™, a proprietary hydroxypropyl beta cyclodextrin formulation in clinical trials for Niemann-Pick Disease Type C1 and in a Phase 2b trial for early Alzheimer’s disease, leveraging data from an Expanded Access program.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cyclo Therapeutics company profile →
GlycoEra
HQ: Switzerland
Website
- Description: Provider of extracellular protein degraders for autoimmune diseases, leveraging its CustomGlycan platform to design bi-functional biologics that selectively degrade circulating or membrane disease-causing proteins, such as autoantibodies, without broadly suppressing the immune system. Offerings include G-LyTACs, a custom glycan engineering platform, and protein degradation therapeutics with applications in oncology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GlycoEra company profile →
Kymab
HQ: United Kingdom
Website
- Description: Provider of fully human monoclonal antibody therapeutics focused on immune-mediated diseases and immuno-oncology, developed using proprietary, integrated IntelliSelect platforms. IntelliSelect Transgenic platforms contain a full diversity of human antibodies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kymab company profile →
Jnana Therapeutics
HQ: United States
Website
- Description: Provider of chemoproteomics-driven drug discovery via its RAPID platform to identify small-molecule medicines for a range of diseases; developing JNT-517, an allosteric SLC6A19 inhibitor for phenylketonuria to reduce plasma phenylalanine; advancing programs for autoimmune and inflammatory conditions; and collaborating with biopharma in cancer, immune-mediated, and neurological diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Jnana Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Futura Medical
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Futura Medical
2.2 - Growth funds investing in similar companies to Futura Medical
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Futura Medical
4.2 - Public trading comparable groups for Futura Medical
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →